Chemotherapy of Brain Tumours

  • J. Hildebrand
  • J. Brihaye
Part of the Advances and Technical Standards in Neurosurgery book series (NEUROSURGERY, volume 5)

Abstract

The choice of drugs in antineoplastic chemotherapy remains still largely empirical. A better understanding of some basic phenomena such as metabolism and kinetics of malignant cells is essential for a more rational choice and more efficient routes and schedules of anticancerous drug administration. Equally important, particularly for brain tumours, are pharmacological factors: the passage of drugs across the blood-brain barrier, their liposolubility, state of ionization, diffusion from cerebrospinal fluid (CSF) into the tumours, and their half-life in various compartments of the body.

Keywords

Brain Tumour Malignant Glioma Glioblastoma Multiforme Malignant Brain Tumour Antineoplastic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ariel, I. M., 1961: Intra-arterial chemotherapy for metastatic cancer to the brain. Amer. J. Surg. 102, 647–650.PubMedCrossRefGoogle Scholar
  2. Aronson, H. A., Flanigan, S., Mark, J. B. D., 1963: Chemotherapy of malignant brain tumors using regional perfusion. I. Technic and patient selection. Ann. Surg. 157, 394–399.PubMedCrossRefGoogle Scholar
  3. Ausman, J. I., Shapiro, W. R., Rall, D. P., 1970: Studies on the chemotherapy of experimental brain tumors: Development G experimental model. Cancer Res. 30, 2394–2400.PubMedGoogle Scholar
  4. Ausman, J. I., Levin, V. A., Brown, W. E., Rall, D. P., Fenstermacher, J. D., 1977: Brain-tumor chemotherapy. Pharmacological principles derived from a monkey brain-tumor model. J. Neurosurg. 46, 155–164.PubMedCrossRefGoogle Scholar
  5. Band, P. R., Weir, B. K. A., Urtasun, R. C., Blain, G., McLeon, D., Wilson, F., Mielke, B., Grace, M., 1974: Radiotherapy and CCNU in grade III and IV astrocytoma. ASCO abstracts 25, 161.Google Scholar
  6. Barker, M., Hoshino, T., Gurcay, O., Wilson, C. B., Nielsen, S. L., Downie, R., Eliason, J., 1973: Development of an animal brain tumor. Model and its response to therapy with 1,3-BIS(2-Chloroethyl)-1-introsourea. Cancer Res. 33,976–986.PubMedGoogle Scholar
  7. Bellman, S., Hugosson, R., Johansson, B., Sjögren, S. E., 1964: Chemotherapy of five supratentorial malignant gliomas with intra-arterial infusion of methotrexate. Acta Chir. Scand. 127,569–574.PubMedGoogle Scholar
  8. Bleyer, W. A., Drake, J. C., Chabner, B. A., 1973: Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukemia. IV. Engl. J. Med. 289, 770–773.Google Scholar
  9. Brihaye, J., Gueuning, Ch., Huysman, E., 1971: Les tumeurs cérébrales. In: chimiothérapie et chirurgie. Acta Chir. Belg., suppl. 1, 42–59.Google Scholar
  10. Brisman, R., Houseplan, E. M., Chang, C., Duffy, P., Balis, E., 1976: Adjuvant nitrosourea therapy for glioblastoma. Arch. Neurol. 33, 745–750.PubMedGoogle Scholar
  11. Brouty-Boye, G., Constans, J. P., 1976: Action comparative in vitro de divers agents antimitotiques sur des lignées cellulaires établies à partir de tumeurs cérébrales humaines. Neurochirurgie 22,69–76.PubMedGoogle Scholar
  12. Burgess, E. A., Sylven, D., 1962: Glucose, lactate and lactic dehydrogenase activity in normal interstitial fluid and that of mouse tumours. Cancer Res. 22,581–587.PubMedGoogle Scholar
  13. Chassard, J. L., Dutou, L., Gerard, J. P., Papillon, J., 1975: La radiothérapie postopératoire des gliomes hémisphériques de l’adulte. A propos d’une statistique de 134 observations. Neurochirurgie 21,377–390.PubMedGoogle Scholar
  14. Chen, T. T., Meahey, J., Jr., 1973: Effect of corticosteroid on protein and nucleic acid synthetics in human glial tumor cells. Cancer Res. 33, 1721–1723.PubMedGoogle Scholar
  15. Cuatico, W., Cho, J. R., Spiegelman, S., 1973: Particles with RNA of high molecular weight and RNA-directed DNA polymerose in human brain tumors. Puec. Nat. Acad. Sci. 70,2789–2793.CrossRefGoogle Scholar
  16. Davis, P. L., Shumway, M. H., Siu, B., 1958: Triethylenethiophosphoramide in treatment of metastatic cerebral malignancy. JAMA 167, 726–727.Google Scholar
  17. Davis, P. L., Shumway, M. H., 1961: Thiotepa in treatment of metastatic cerebral malignancy. JAMA 175, 714–715.PubMedGoogle Scholar
  18. Denlinger, R. H., Koestner, A., Swenberg, J. A., 1973: An experimental model for selective production of neoplasms of the peripheral nervous system. Acta Neuropathol. 23, 219–229.Google Scholar
  19. Eckman, W. W., Patlak, C. S., Fenstermacher, J. D., 1974: A critical evaluation of the principles governing the advantages of intra-arterial infusions. J. Pharmacokinet. Biopharm. 2, 257–285.PubMedCrossRefGoogle Scholar
  20. Edland, R. W., Javid, M., Ansfield, F. J., 1971: Glioblastoma multiforme. An analysis of the results of post operative radiotherapy alone versus radiotherapy and concomitant s’fluorouracil. Amer. J. Roentg. 3, 337–342.Google Scholar
  21. Engelhardt, P., 1976: Intrathecal cystostatic therapy of meningeal carcinomatosis. Autoradiographie investigations of the CSF cells. J. Neurol. 213, 309–315.PubMedCrossRefGoogle Scholar
  22. EORTC Brain Tumor Group, 1976: Effect of CCNU on survival, rate of objective remission and duration of free interval in patients in the malignant brain gliomafirst evaluation. Eur. J. Cancer 12,41–45.CrossRefGoogle Scholar
  23. Fewer, D., Wilson, C. B., Boldrey, E. B., Enot, J. K., 1972: Phase II study of CCNUNSC 79037 in the treatment of brain tumours. Cancer Chemother. Rep. 56, 421–427.Google Scholar
  24. Fewer, D., Powell, M. R., 1972: The chemotherapy of brain tumours. Clinical experience in the carmustine (BCNU) and vincristine. JAMA 222, 549–552.PubMedCrossRefGoogle Scholar
  25. Frankel, S. A., German, W. J., 1958: Glioblastoma multiforme. Review of 219 cases with regard to natural history, pathology, diagnostic methods and treatment. J. Neurosurg. 15,489–503.PubMedCrossRefGoogle Scholar
  26. French, J. D., West, P. M., Amerongen, F. K. von, Magoun, H. W., 1952: Effects of intracarotid administration of nitrogen mustard on normal brain and brain tumors. J. Neurosurg. 9, 378–389.PubMedCrossRefGoogle Scholar
  27. Fumagalli, R., Grossi-Paoletti, E., Paoletti, P., Paoletti, R., 1964: Studies on lipids in brain donors. I occurence and signification of sterol precursors of cholesterol in human brain tumors. J. Neurosurg. 2, 561–565.Google Scholar
  28. Garfield, J., Dayan, A. D., 1973: Postoperative intracavity chemotherapy of malignant gliomas. A preliminary study using methotrexate. J. Neurosurg. 39, 315–322.PubMedCrossRefGoogle Scholar
  29. Garfield, J., Dayan, A. D., Weller, R. O., 1975: Postoperative intracavity chemotherapy of malignant supratentorial astrocytomas using BCNU. Clinical Oncology 1, 213–222.PubMedGoogle Scholar
  30. Geran, R. I., Congleton, G. F., Dudeck, L. E., Abbott, B. J. de, Gargus, J. L., 1974: A mouse ependymoblastoma as an experimental model for screening potential antimoplastic drugs. Cancer Chemother. Rep. 4, 53–87.Google Scholar
  31. Grasso, R. J., 1976: Transient inhibition of cell proliferation by glucocorticoids in rat glioma monolayer cultures. Abstracts Am. Ass. Cancer Res., p. 82.Google Scholar
  32. Greenhouse, A. H., Neubuerger, K. T., Bowerman, D. L., 1964: Brain damage after intracarotid infusion of methotrexate. Arch. Neurol. 11, 618–625.PubMedGoogle Scholar
  33. Gurcay, O., Wilson, C. B., Barker, M., Eliason, J., 1971: Corticoid effects on transplantable rat glioma. Arch. Neurol. 24, 266–269.PubMedGoogle Scholar
  34. Gutin, Ph., Weiss, H. D., Wiernik, P. H., Walker, M. D., 1976: Intrathecal N, N’, N“-Triethylenethiophosphamide [Thio-Tepa (NSC 6396)] in the treatment of malignant meningeal disease. Phase I-CII study. Cancer 38, 1471–1475.Google Scholar
  35. Hayakawa, T., Yamada, R., Kanai, N., Kuroda, R., Ushio, Y., Higashi, H., Mogami, H., 1970: Intrathecal chemotherapy. Selection of cytostatic agents. Brit. J. Cancer 24, 489–497.CrossRefGoogle Scholar
  36. Hayakawa, T., Ushio, Y., Morimoto, K., Hasegawa, H., Mogami, H., Horibata, K., 1976: Uptake of bleomycin by human brain tumours. J. Neurol. Neurosurg. Psych. 39, 341–349.CrossRefGoogle Scholar
  37. Heppner, F., Diemath, H. E., 1963: Lokale Chemotherapie der Hirntumoren. Acta Neurochir. (Wien) 11, 287–293.CrossRefGoogle Scholar
  38. Hildebrand, J., Levin, S., 1973: Enzymatic activities in cerebrospinal fluid in patients with neurological diseases. Acta Neurol. Belg. 73, 229–240.PubMedGoogle Scholar
  39. Hildebrand, J., Brihaye, J., Wagenknecht, L., Michel, J., Kenis, Y., 1975: Combination therapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors. Eur. J. Cancer 11, 585–587.PubMedCrossRefGoogle Scholar
  40. Hoshino, T., Barker, M., Wilson, C. B., Boldrey, E. B., Fewer, D., 1972: Cell kinetics of human gliomas. J. Neurosurg. 37, 15–26.PubMedCrossRefGoogle Scholar
  41. Hoshino, T., Barker, M., Wilson, C. B., 1975: The kinetics of cultured human glioma cells. Acta Neuropathol. 32, 235–244.PubMedCrossRefGoogle Scholar
  42. Hoshino, T., Wilson, C. B., Rosenblum, M. L., Barker, M., 1975: Chemotherapeutic implications of growth fraction and cell cycle time in glioblastomas. J. Neurosurg. 43, 127–135.PubMedCrossRefGoogle Scholar
  43. Introzzi, G., Paoletti, P., Pezzotta, S., Robustelli della Cuna, G., Rodriguezy Baena, R., 1975: The use of BCNLT in chemotherapy of tumors of the central nervous system. J. Neurosurg. Sei. 19, 223–225.Google Scholar
  44. Jelsma, R., Bucy, P. C., 1967: The treatment of glioblastoma multiforme of the brain. J. Neurosurg. 27, 388–400.PubMedCrossRefGoogle Scholar
  45. Jelsma, R., Bucy, P. C., 1969: Glioblastoma multiforme. Its treatment and some factors. Effecting survival. Arch. Neurol. 20, 161–171.PubMedGoogle Scholar
  46. Kennedy, B. J., Brown, J. H., Yarbo, J. W., 1965: Mithramycin (NSC-24559) therapy for primary glioblastomas. Cancer Chemother. Rep. 48, 59–63.PubMedGoogle Scholar
  47. Kennedy, B. J., Yarbo, J. W., Kickertz, V., Sandberg-Wollheim, M., 1968: Effects of mithramycin on a mouse glioma. Cancer Res. 28, 91–97.PubMedGoogle Scholar
  48. Khanna, H. L., Bailey, I. C., Taylor, A. R., Grebbell, F. S., 1969: Epodyl in the management of cerebral glioma. Neurology 19, 570–573.PubMedGoogle Scholar
  49. Koestner, A., Swenberg, J. A., Wechsler, W., 1972: Experimental tumors of the nervous system induced by resorptive N-nitrosourea compounds. In: Progress in Experimental Tumor Research 17, 9–30. Editor G. Bingham Basel: S. Karger.Google Scholar
  50. Kontras, S. B., Newton, W. A., Sayers, M. P., 1962: Preliminary report on the use of intrathecal methotrexate in brain tumors of childhood. Proc. Amer. Ass. Cancer Res. 3, 151.Google Scholar
  51. Koo, A. H., Fewer, D., Wilson, C. B., Newton, T. H., 1972: Lack of correlation between clinical and angiographie findings in patients with brain tumours under BCNU chemotherapy. J. Neurosurg. 37, 9–14.PubMedCrossRefGoogle Scholar
  52. Kumar, A. R. V., Renaudin, J., Wilson, C. B., Boldrey, E. B., Enot, K. J., Levin, V. A., 1974: Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study. J. Neurosurg. 40,365–371.CrossRefGoogle Scholar
  53. Kun-Yu Wu, K., Jacobsen, C. D., Hoak, J. C., 1973: Plasminogen in normal and abnormal human cerebrospinal fluid. Arch. Neurol. 28, 64–66.Google Scholar
  54. Lassman, L. P., Pearce, G. W., Gang, J., 1965: Sensitivity of intracranial gliomas to vincristine sulphate. Lancet, no. 7380, 296–297.CrossRefGoogle Scholar
  55. Laurent, G., Atassi, G., Hildebrand, J., 1976: Potentiation of 1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea (CCNU) by amphoterican B (AMB) in marine ependymoblastoma. Cancer Res. 36, 4069–4073.PubMedGoogle Scholar
  56. Levin, V. A., Shapiro, W. R., Clancy, T. P., Oliverio, V. T., 1970: The uptake, distribution, and antitumor activity of 1-(2-chloroethyl)-3-cyclohexyl-3-nitrosourea in the murin glioma. Cancer Res. 30,2451–2455.PubMedGoogle Scholar
  57. Levin, V. A., Kabra, P., 1975: Brain and tumor pharmacokinetics of BCNU and CCNU following I.V. and intracarotid artery (I.C.A.) administration. Proc. Amer. Ass. Cancer Res. 16,19.Google Scholar
  58. Levine, M. A., Walker, M. D., Weiss, H. D., 1974: Intravenous methyl-CCNU in the treatment of malignant glioma. ASCO Abstracts, p. 167.Google Scholar
  59. Long, J. M., 1970: Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J. Neurosurg. 32,127–144.PubMedCrossRefGoogle Scholar
  60. Luyendijk, W., Beusekom, G. Th. van, 1966: Chemotherapy of cerebral gliomas with intracarotid methotrexate-infusion. Acta Neurochir. (Wien) 15,234–248.CrossRefGoogle Scholar
  61. Matricali, B., 1974: Chemotherapie van het maligne gliomaa cerebri. Nederland. Tijdschr. Geneesk. (in press).Google Scholar
  62. Maker, H. S., Lehrer, G. M., Silides, D. J., Weiss, C., 1969: Circulatory factors in the carbohydrate metabolism of an experimental glial neoplasm. Ann. N.Y. Acad. Sei. 195,461–471.CrossRefGoogle Scholar
  63. Marne, L., Nouet, J. P., Robert, J., Chai, N., Houdart, R., 1973: Use of radioactive bleomycin to detect malignant intracranial tumors. J. Neurosurg. 39,735–741.CrossRefGoogle Scholar
  64. Mark, V. H., Kjellberg, R. N., Ojemann, R. G., Soloway, A. H., 1960: Treatment of malignant brain tumors with alkylating agents. (Thiotepa triethylene thiophosphoramide): Its differential concentration and toxicity after arterial infusion. Neurology 10, 772–776.PubMedGoogle Scholar
  65. Mathe, G., Kenis, Y., 1975: La chimiothérapie des cancers. Paris: Expansion scientifique française. 1975.Google Scholar
  66. Morton, L. J., Heby, O., Levin, V. A., Lubich, W. P., Crafts, D. C., Wilson, C. B., 1976: The relationship of polyamines in cerebrospinal fluid to the presence of central nervous system tumors. Cancer Res. 36, 973–977.Google Scholar
  67. Newton, K. A., 1962: Intermittent intra-arterial injection and continuous intravenous infusion in the treatment of advanced cancer. Proc. Roy. Soc. Med. 55, 646–649.PubMedGoogle Scholar
  68. Newton, W. A., Jr., Sayers, H. P., 1965: Intrathecal methotrexate therapy of brain tumors of childhood. Proc. Amer. Ass. Cancer Res. 4,190.Google Scholar
  69. Newton, W. A., Sayers, M. P., Samuels, L. D., 1968: Intrathecal methotrexate therapy NSC-740 for brain tumors in children. Cancer Chemother. Rep. 52, 257–261.PubMedGoogle Scholar
  70. Norrel, H., Wilson, C. B., 1967: Brain tumor chemotherapy with methotrexate given intrathecally. JAMA 201, 93–95.CrossRefGoogle Scholar
  71. Ommaya, A. K., Rubin, R. C., Henderson, E. S., Rall, D. P., Gieseke, F. G., Bering, E. A., Bagan, M., 1965: A new approach to the treatment of inoperable brain tumors. Med. Ann. DC. 34, 455–458.Google Scholar
  72. Perese, D. M., Day, C. E., Chardack, W. M., 1962: Chemotherapy of brain tumors by intra-arterial infusion. J. Neurosurg. 19, 215–219.PubMedCrossRefGoogle Scholar
  73. Pons, A., Armand, J. P., Combes, P. F., Nadal, P., 1975: Survie des malades atteints de tumeurs cérébrales sus-tentorielle primitives, en fonction des associations thérapeutiques. Neurochirurgie 21,408–410.PubMedGoogle Scholar
  74. Price, L. A., Goldie, J. H., Hill, B. T., 1975: Methodichlorophen as anti-tumor drug. Brit. Med. J. 2, 20–21.PubMedCrossRefGoogle Scholar
  75. Pouillart, P., Schwarzenberg, L., Ameil, J. L., Mathe, G., Huguenin, P., Morin, P., Baron, A., Laparre, Ch., Parrot, R., 1975: Combinaisons chimiothérapiques de drogues se potentialisant. III. Application aux tumeurs primitives du système nerveux central. Nouv. Presse Méd. 4, 713–721.Google Scholar
  76. Ransohoff, J., Martin, B. F., Medrek, T. J., Harris, M. N., Golomb, F. M., Wright, J. C., 1965: Preliminary clinical study of mithramycin (NSC-24559) in primary tumors of the central nervous system. Cancer Chemother. Rep. 49,51–57.PubMedGoogle Scholar
  77. Reagan, T. J., Bisel, H. F., Childs, D. S., Layton, D. D., Rhoton, A. L., Taylor, W. F., 1976: Controlled study of CCNU and radiation therapy in malignant astrocytoma. J. Neurosurg. 44, 186–190.PubMedCrossRefGoogle Scholar
  78. Renaudin, J., Fewer, D., Wilson, C. B., Boldrey, E. B., Calogero, J., Enot, K. J., 1973: Dose dependency of Decadron in patients with partially excised brain tumors. J. Neurosurg. 39,302–305.PubMedCrossRefGoogle Scholar
  79. Rieselbach, R. E., Dichiro, G., Freireich, E. J., Rail, D. P., 1962: Subarachnoid distribution of drugs after lumbar injection. New Engl. J. Med. 267,1273–1278.PubMedCrossRefGoogle Scholar
  80. Ringkjeb, R., 1968: Treatment of intracranial gliomas and metastatic carcinomas by local application of cytostatic agents. Acta Neurol. Scand. 44, 318–322.CrossRefGoogle Scholar
  81. Rosen, J. M., Rosen, F., Milholland, R. J., Nichol, C. H., 1970: Effects of cortisol on DNA metabolism in the sensitive and resistant lines of mouse lymphoma. Cancer Res. 30,1129–1136.PubMedGoogle Scholar
  82. Rosenblum, M. L., Bowie, D. L., Walker, M. D., 1973: Diffusion in vitro and in vivo of 1- (2-chloroethyl)-3- (trans-4-methylcyclohexyl)-1-introsourea from silicone rubber capsules, a potentially new mode of chemotherapy administration. Cancer Res. 33, 906–914.PubMedGoogle Scholar
  83. Rosenblum, M. L., Reynolds, A. F., Smith, K. A., Rumach, B. H., Walker, M. D., 1973: Chloroethylcycloethyl-introsourea (CCNU) in the treatment of malignant brain tumours. J. Neurosurg. 39, 306–314.PubMedCrossRefGoogle Scholar
  84. Rosenblum, M. L., Wheeler, K. T., Wilson, C. B., Barker, M., Knebel, K. D., 1975: In vitro evaluation of in vivo Brain tumor chemotherapy with 1,3-BIS- (2-chloroethyl)-1-introsourea. Cancer Res. 35, 1387–1391.PubMedGoogle Scholar
  85. Rosenblum, M. L., Knebel, K. D., Vasquez, D. A., Wilson, C. B., 1977: Brain-tumor therapy. Quantitative analysis using a model system. J. Neurosurg. 46,145–154.PubMedCrossRefGoogle Scholar
  86. Rosenstock, J. G., Evans, A. E., Schut, L., 1976: Response to vincristine of recurrent brain tumors in children. J. Neurosurg. 45, 135–140.PubMedCrossRefGoogle Scholar
  87. Roth, J. G., Elvidge, A. R., 1960: Glioblastoma multiforme: a clinical survey. J. Neurosurg. 172,736–750.Google Scholar
  88. Rubin, R. C., Ommaya, A. K., Henderson, E. S., Bering, E. A., Rall, D. P., 1966: Cerebrospinal fluid perfusion for central nervous system neoplasms. Neurology 16, 680–692.PubMedGoogle Scholar
  89. Rubin, R. C., Larson, R., Rall, D. P., 1966: 8-Azaguanine (NSC-749). I. Preclinical toxicity studies and a preliminary report on intrathecal perfusion therapy for patients. Cancer Chemother. Rep. 50,283–286.PubMedGoogle Scholar
  90. Rubin, R., Owens, E., Rall, D., 1968: Transport of methotrexate by the choroid plexus. Cancer Res. 13,689–694.Google Scholar
  91. Ruderman, N. B., Hall, T. C., 1965: Use of glucocorticoids in paliative treatment of metastatic brain tumors. Cancer 18, 298–306.PubMedCrossRefGoogle Scholar
  92. Serez, R. J., Campbell, R. J., Laws, E. R., Jr., 1977: Chemotherapeutic trials on human malignant astrocytomas in organ culture. J. Neurosurg. 46,320–327.CrossRefGoogle Scholar
  93. Sano, K., Hoshino, T., Nagai, M., 1968: Radiosensitization of brain tumor cells with a thymidine analogue (Bromouridine). J. Neurosurg. 28,530–538.PubMedCrossRefGoogle Scholar
  94. Sano, K., Hoshino, T., Nagai, M., Tsuchida, T., Sato, F., 1966: Studies on a radiosensitizer (5-Bromo-2Deoxyuridine) in the treatment of malignant brain tumours. Neurol. med. chir. 8,227–231.CrossRefGoogle Scholar
  95. Sartorelli, A. C., Johns, D. G., 1974: Antineoplastic and Immunosuppressive Agents. Berlin-Heidelberg-New York: Springer. 1974.Google Scholar
  96. Schochet, S. S., Lampert, P. W., Earle, K. M., 1968: Neuronal changes induced by intrathecal vincristine sulfate. J. Neuropath. Exp. Neurol. 27, 654–658.CrossRefGoogle Scholar
  97. Schochet, S. S., Lampert, P. W., Earle, K. M., 1969: Oligodendroglial changes induced by intrathecal vincristine sulfate. Exp. Neurol. 1969, 23, 113–119.PubMedCrossRefGoogle Scholar
  98. Seil, F. J., Lampert, P. W., 1968: Neurofibrillary tangles induced by vincristine and vinblastine sulfate in central and peripheral neurons in vitro. Exp. Neurol. 21,219–230.PubMedCrossRefGoogle Scholar
  99. Shapiro, W. R., 1972: Effect of 1-(2-Chloriethyl)-3-cyclohexyl-1-nitrosourea CCNU (NSC-79037) in sesame oil administrated intramuscularly in the treatment of experimental brain tumors. Cancer Chemother. Rep. 56, 457–463.PubMedGoogle Scholar
  100. Shapiro, W. R., Ausman, J. I., 1969: The Chemotherapy of Brain Tumors: A Clinical and Experimental Review. In: Recent Advances in Neurology, Chap. IV, 150–235. Edited by F. Plum. Philadelphia: F. A. Davis Company.Google Scholar
  101. Shapiro, W. R., Ausman, J. I., Rall, D. P., 1970: Studies on the chemotherapy of experimental brain tumors. Evaluation of 1,3-Bis-(2-Chloriethyl)-1-introsourea, cyclophosphanide, mithramycine, and methotrexate. Cancer Res. 30,2401–2413.PubMedGoogle Scholar
  102. Shapiro, W. R., 1971: Studies on the chemotherapy of experimental brain tumors: Evaluation of 1-(2-chloroethyl)-3-cyclotrexyl-1-introsourea, Vincristine and 5-Fluoroceracil. J. Nath. Cancer Inst. 46, 359–368.Google Scholar
  103. Shapiro, W. R.,Chernik, N. L., Posner, J. B., 1973: Necrotizing encephalopathy following intra-ventricular instillation of methotrexate. Arch. Neurol. 28, 96–102.PubMedGoogle Scholar
  104. Shapiro, W. R., 1974: The chemotherapy of intracerebral and subcutaneous murine gliomas. Arch. Neurol. 30, 222–226.PubMedGoogle Scholar
  105. Shapiro, W. R., Young, D. F., Metha, B. M., 1975: Methotrexate: distribution in cerebrospinal fluid after intravenous ventricular and lumbar injections. N. Engl. J. Med. 293,161–166.PubMedCrossRefGoogle Scholar
  106. Smith, B., 1975: Brain damage after intrathecal metotrexate. J. Neurol. Neurosurg. Psyehiat. 38,810–815.CrossRefGoogle Scholar
  107. Stähelin, H., 1970: 4’-Demethyl-epipodopnyllotoxin thenylidene glucoside (VNI26) a podophyllum compound with a new mechanism of action. Europ. J. Cancer 6, 303–311.CrossRefGoogle Scholar
  108. Sugiura, K., 1967: Effect of 1,3-Bis-(2-chloroethyl)-1-introsourea (NSC 409962) and two related compounds on a spectrum of tumors. Cancer Res. 27, 179–189.PubMedGoogle Scholar
  109. Sullivan, R. D., 1962: Continuous arterial infusion. Cancer chemotherapy. Surg. Clin. North Am. 1–32.Google Scholar
  110. Tator, C. H., 1971: Uptake of tritiated methotrexate by an experimental glioma. Cancer Res. 31,1600–1605.PubMedGoogle Scholar
  111. Tator, C. H., 1972: Chemotherapy of brain tumors. Uptake of tritiated methotrexate by a transplantable intracerebral ependymoblastome in mice. J. Neurosurg. 37, 1–8.PubMedCrossRefGoogle Scholar
  112. Tator, C. H., Wassenaar, W., Day, A., Wei Sum So, 1977: Therapy of an experimental glioma with systemic or intraneoplastic methotrexate or radiation. J. Neurosurg. 46, 175–184.PubMedCrossRefGoogle Scholar
  113. Tator, C. H., Wassenaar, W., 1977: Intraneoplastic injection of methotrexate for experimental brain-tumor chemotherapy. J. Neurosurg. 46, 165–174.PubMedCrossRefGoogle Scholar
  114. Tator, C. H., 1977: Intraneoplastic injection of CCNU for experimental brain tumor chemotherapy. Surg. Neurol. 7, 73–77.PubMedGoogle Scholar
  115. Taveras, J. M., Thompson, H. G., Pool, J. L., 1962: Should we treat glioblastoma multiforme? A study of survival in 425 cases. Amer. J. Roentgenol. Radium Ther. Nucl. Med. 87,473–479.Google Scholar
  116. Trabucchi, M., Cerri, C., Spano, P. F., Kumakuua, K., 1977: Guanosine 3’-5’-monophosphate in the CSF of neurological patients. Arch. Neurol. 34,12–13.PubMedGoogle Scholar
  117. Ushio, Y., Hayakawa, T., Mogami, H., 1974: Uptake of triated methotrexate by mouse brain tumors after intravenous or intrathecal administration. J. Neurosurg. 40, 706–716.PubMedCrossRefGoogle Scholar
  118. Putten, L. M. van, Keizer, H. J., Mulder, J. H., 1976: Synchronization in tumour chemotherapy. Europ. J. Cancer 12,79–85.Google Scholar
  119. Walker, M. D., Hurwitz, B. S., 1970: BCNU (1,3-Bis-(2-Chloroethyl)-1-Nitrosourea; NSC-409962) in the treatment of malignant brain tumor—a preliminary report. Cancer Chemother. Rep. 54,263–271.PubMedGoogle Scholar
  120. Walker, M. D., Alexander, E., Jr., Hunt, W. E., Leventhal, L. M., Mahaley, M. S., Jr., Mealey, J., Norrell, H. A., Owens, G., Ransohoff, J., Wilson, C. B., Gehan, E. A., 1976: Evaluation of mithramycin in the treatment of anaplastic gliomas. J. Neurosurg. 44, 655–667.PubMedCrossRefGoogle Scholar
  121. Walker, M. D., Gehan, E. A., 1972: An evaluation of BCNU and irradiation alone and in combination for the treatment of malignant gliomas. Proc. Am. Ass. Cancer Res. 13, 67.Google Scholar
  122. Walker, M. D., 1975: Chemotherapy: Adjuvant to surgery and radiation therapy. Seminars in Oncology 2,69–72.PubMedGoogle Scholar
  123. Walker, M. D., Strike, T. A., 1976: An evaluation of methyl CCNU, BCNU and radiotherapy in treatment of malignant glioma. Proc. AACR, p. 163.Google Scholar
  124. Wassenaar, W., Tator, C. H., Wei Sum So, 1973: The development of an intracerebral glioma model for brain tumor chemotherapy. J. Neurosurg. 39,293–301.PubMedCrossRefGoogle Scholar
  125. Weir, B., Band, P., Urtasun, R., Blain, G., McLean, D., Wilson, F., Mielke, B., Grace, M., 1976: Radiotherapy and CCNU in the treatment of supratentorial astrocytomas. J. Neurosurg. 45, 129–134.PubMedCrossRefGoogle Scholar
  126. Weiss, J. F., Cravioto, H., Bennet, K., Weiss, E. C., Ransohoff, J., 1976: Desmosterol in human and experimental brain tumors in tissue culture. Arch. Neurol. 33, 180–182.PubMedGoogle Scholar
  127. Whiteside, J. A., Philips, F. S., Dargeon, H. W., Burcenal, J. H., 1958: Intrathecal amethosterin in neurological manifestations of leukemia. Arch. Intern. Med. 101,279–285.Google Scholar
  128. Willson, N., Duffy, P. E., 1974: Morphologic changes associated with combined BCNU and radiation therapy in glioblastoma multiforme. Neurology 10, 465–471.Google Scholar
  129. Wilson, C. B., Weilbaecher, R., McGarry, P., 1963: Characteristics of human brain tumors in tissue cultures and animal host. Surgical Forum 14, 430–431.PubMedGoogle Scholar
  130. Wilson, C. B.,1964: Chemotherapy of brain tumors by continuous arterial infusion. Surgery 55, 640–653.PubMedGoogle Scholar
  131. Wilson, C. B., Barker, M., 1965: Sensitivity of cell cultures of neural tumors to vinblastine sulfate (NSC-49842). Cancer Chemother. Rep. 44,9–13.PubMedGoogle Scholar
  132. Wilson, C. B., Norrell, H., Jr., Barker, M., 1967: Intrathecal injection of methotrexate (NSC-740) in transplanted brain tumors. Cancer Chemother. Rep. 51, 1–5.PubMedGoogle Scholar
  133. Wilson, C. B., Hoshino, T., 1969: Current trends in the chemotherapy of brain tumors with special reference to glioblastomas. J. Neurosurg. 31, 589–603.PubMedCrossRefGoogle Scholar
  134. Wilson, C. B., 1969: Current trends in the chemotherapy of brain tumors with special reference to glioblastomas. J. Neurosurg. 31,589–603.PubMedCrossRefGoogle Scholar
  135. Wilson, C. B., Boldrey, E. B., Enot, J. K., 1970: 1,3-Bis-(2-chloroethyl)-1-nitrosourea (N.S.C. 409962) in the treatment of brain tumours. Cancer Chemother. Rep. 54, 273–281.PubMedGoogle Scholar
  136. Wilson, C. B., 1976: Chemotherapy of Brain Tumors. In: Advances in Neurology, Vol. 15, p. 361–368. Edited by Thompson, R. A., Green, J. R. Berlin-Heidelberg-New York: Springer.Google Scholar
  137. Wilson, C. B., Gutin, P., Boldrey, E. B., Crafts, D., Levin, V. A., Enot, K. J., 1976: Single-agent chemotherapy of brain tumors. Arch. Neurol. 33, 739–744.PubMedGoogle Scholar
  138. Wilson, C. B., Yorke, Ch., Jr., Levin, V. A., 1977: Intracranial Malignant Growth, Primary and Metastatic. In: Current Problems in Cancer. Editor Hickey, R. C., Year Book Medical publishers.Google Scholar
  139. Wodinsky, I., Kensler, C. J., Rail, D. P., 1969: The induction and transplantation of brain tumors in neonate beagles. Abstracts Am. Assoc. Cancer Res., p. 99.Google Scholar
  140. Woodhall, B., Hall, K., Mahaley, S., Jackson, J., 1959: Chemotherapy of brain cancer: experimental and clinical studies in localized hypothermic cerebral perfusion. Ann. Surg. 150,640–652.PubMedCrossRefGoogle Scholar
  141. Woodhall, B., 1960: Brain perfusion. Cancer Chemother. Rep. 10,11–13.PubMedGoogle Scholar
  142. Woodhall, B., 1960: Results of perfusion¡ªneural tumors. Cancer Chemother. Rep. 10,93–98.PubMedGoogle Scholar
  143. Woodhall, B., Pickrell, K. L., Georgiade, N. G., Mahaley, M. S., Jr., Dukes, H. T., 1960: Effect of hypothermia upon cancer chemotherapy. Application to external cancers of head and face structure. Ann. Surg. 151, 750–759.PubMedCrossRefGoogle Scholar
  144. Wright, R. L., Soloway, A. H., 1961: The efficacy of intracarotid injections. Neurology 11, 922–924.Google Scholar
  145. Yohn, D. S., 1972: Oncogenic Viruses: Expectations and Applications in Neuropathology. Progress in Experimental Tumor Research, Vol. 17, p. 74–92. Editor: G. Bingham. Basel: S. Karger.Google Scholar
  146. Young, H. F., Sakalas, R., Kaplan, A. M. Ph., 1976: Inhibition of cell-mediated immunity in patients with brain tumors. Surg. Neurol. 5, 19–22.PubMedGoogle Scholar
  147. Zagler, R. F., Frisby, S. A., Oliverio, V. T., 1973: The effects of antibiotics and cancer chemotherapic agents on the cellular transport and antitumor activity of methotrexate in LIZIO mur nie leukemia. Cancer Res. 33, 1670–1676.Google Scholar

Copyright information

© Springer-Verlag/Wien 1978

Authors and Affiliations

  • J. Hildebrand
    • 1
  • J. Brihaye
    • 1
  1. 1.Departments of Internal Medicine and Neurosurgery, Institut BordetUniversity of BrusselsBelgium

Personalised recommendations